Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients

Urticaria Chronic Clinical Trial

Official title:
A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of UB-221 as an Add-on Therapy in Patients With Chronic Spontaneous Urticaria

Status Completed

Clinical Trial Summary

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of UB-221 as an add-on therapy in patients with Chronic Spontaneous Urticaria.

Clinical Trial Description

This is a phase I, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of UB-221 as an add-on therapy in patients with Chronic Spontaneous Urticaria. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03632291
Study type	Interventional
Source	United BioPharma
Contact
Status	Completed
Phase	Phase 1
Start date	April 9, 2019
Completion date	January 19, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03111628` - Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU)	Phase 4
Recruiting	`NCT03151902` - Detection of Viral Particels in Urticaria Patients
Completed	`NCT05461456` - Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%	Phase 1